A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
Hirakawa M, Sato Y, Ohnuma H, Takayama T, Sagawa T, Nobuoka T, Harada K, Miyamoto H, Sato Y, Takahashi Y, Katsuki S, Hirayama M, Takahashi M, Ono M, Maeda M, Takada K, Hayashi T, Sato T, Miyanishi K, Takimoto R, Kobune M, Hirata K, Kato J.
Hirakawa M, et al. Among authors: takayama t.
Cancer Chemother Pharmacol. 2013 Mar;71(3):789-97. doi: 10.1007/s00280-013-2073-5. Epub 2013 Jan 22.
Cancer Chemother Pharmacol. 2013.
PMID: 23338051
Clinical Trial.